

# PKC- $\theta$ [pT538] ABfinity™ Recombinant Rabbit Monoclonal Antibody - Purified



**REF** Catalog no. 700043

(See product label for lot information)

**Clone/PAD:** F4H4L1  
**Isotype:** IgG  
**Gene ID:** 5588  
**Protein Acc. no.:** Q04759  
**Qty:** 100  $\mu$ g  
**Volume:** 200  $\mu$ l  
**Concentration:** 0.5 mg/ml

## Formulation

PBS + 0.09% azide

## Immunogen

A peptide corresponding to amino acids 531-539 of Q04759.

## Immunogen sequence

LGDAKTN[pT]F

## Reactivity

This antibody reacts with human PKC- $\theta$  [pT538]. Based on sequence identity and similarity, reactivity to mouse, rat, chimpanzee, bovine, and *Xenopus* is expected.

## Specificity

This antibody is specific for PKC- $\theta$  [pT538] and does not recognize non-phosphorylated PKC- $\theta$

## Storage

2-8°C for up to 1 mo, -20°C for long term storage. Avoid repeated freezing and thawing.



## Expiration Date

Expires one year from date of receipt when stored as instructed.

## Validated Applications:

	Species	Test Material	Concentration
<b>Western Blotting</b>	human	Jurkat	2-4 $\mu$ g/ml
<b>Immunohistochemistry</b>	human	breast carcinoma	4-6 $\mu$ g/ml
<b>Immunofluorescence</b>	human	HeLa	8-12 $\mu$ g/ml
<b>Flow Cytometry</b>	human	Jurkat + PMA	0.1-0.5 $\mu$ g/test

## Background

Protein Kinase C $\theta$  (PKC $\theta$ ) is an 80 kDa member of the novel group (nPKCs: sensitive to diacylglycerol, phosphatidylserine and phorbol esters) of the PKC family of serine/threonine kinases that are involved in a wide range of physiological processes including mitogenesis, cell survival and homeostasis (2). Transgenic mice over-expressing dominant negative PKC $\theta$  develop hyperinsulinemia (1). PKC $\theta$  is involved in JNK activation and also plays a specialized role in TCR-mediated activation of T and B cells (5,2,6). Through its control of Rap1, PKC $\theta$  establishes a threshold for T cell activation and positively regulates cytokine response and adhesive properties (7). The activation of PKC $\theta$  in T cells is associated with its recruitment to the membrane, and is mediated by PI3-kinase and Vav. PKC $\theta$  is a constitutively competent kinase and is phosphorylated on threonine 538 in the activation loop (3). The phosphorylation of threonine 538 is critical to PKC $\theta$  kinase activity, and plays an important role in PKC $\theta$ -mediated activation of nuclear factor  $\kappa$ B (NF- $\kappa$ B) (3).

## References

1. Serra, C., et al. (2003) Transgenic mice with dominant negative PKC-theta in skeletal muscle: A new model of insulin resistance and obesity. *J. Cell Physiol.* 196:89-97.
2. Dennehy, K.M., et al. (2003) Mitogenic signals through CD28 activate the protein kinase C-NF-kappaB pathway in primary peripheral T cells. *Int. Immunol.* 15:655-663.
3. Liu, Y., et al. (2002) Phosphorylation of the protein kinase C-theta activation loop and hydrophobic motif regulates its kinase activity, but only activation loop phosphorylation is critical to in vivo nuclear-factor-kappaB induction. *Biochem. J.* 361:255-265.
4. Gao, T. and A.C. Newton (2002) The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C. *J. Biol. Chem.* 277:31585-31592.
5. Villalba, M., et al. (2002) Translocation of PKC $\theta$  in T cells is mediated by a nonconventional, PI3-K- and Vav-dependent pathway, but does not absolutely require phospholipase C. *J. Cell Biol.* 157:253-263.
6. Bauer, B., et al. (2001) Complex formation and cooperation of protein kinase C theta and Akt1/protein kinase B alpha in the NF-kappa B transactivation cascade in Jurkat T cells. *J. Biol. Chem.* 276:31627-31634.
7. Letschka T, et al. (2008) PKC-theta selectively controls the adhesion-stimulating molecule Rap1. *Blood* 112: 4617-4627.

For research use only. CAUTION: Not intended for human or animal therapeutic or diagnostic use.


[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.


Rev. 0.0

FORM-00089




**Flow cytometry of Jurkat cells labeled with rabbit anti-PKC- $\theta$  [pT538] (Cat. No. 700043).**

Jurkat cells incubated with 100  $\mu$ M PMA for 1 h prior to being fixed and permeabilized using FIX & PERM<sup>®</sup> (Cat. No. GAS004) reagents. Cells were then stained with (gray trace) 0.1  $\mu$ g anti-PKC- $\theta$  [pT538] followed by Alexa Fluor<sup>®</sup> 488 goat anti-rabbit Ig (Cat. No. A11008). Pre-incubation with the immunogenic phosphopeptide decreased the signal (red trace), whereas incubation with the non-phosphopeptide did not (blue trace).




**Immunohistochemistry of human breast carcinoma tissue labeled with rabbit anti-PKC- $\theta$  [pT538] (Cat. No. 700043).**

FFPE human breast carcinoma tissue was labeled with rabbit anti-PKC- $\theta$  [pT538] (5  $\mu$ g/ml). Tissues were detected with SuperPicTure<sup>™</sup> Polymer DAB (Cat. No.87-8963). Images were taken at 20x magnification. Note cytoplasmic staining in tumor cells.



**Immunocytochemistry of HeLa cells labeled with rabbit anti-PKC- $\theta$  [pT538] (Cat. No. 700043).**

HeLa cells labeled with rabbit anti-PKC- $\theta$  [pT538] (10  $\mu$ g/ml) in the absence of peptides (top panels), and presence of phosphopeptide used as immunogen (bottom panels) or non-phosphopeptide (middle panels). Alexa Fluor<sup>®</sup> 488 goat anti-rabbit (Cat. No. A11008) at 1:1000 was used as secondary antibody. Actin was stained with Alexa Fluor<sup>®</sup> 568 Phalloidin (Cat. No. A12380). Hoechst only (left), PKC- $\theta$  [pT538] (AF488) signal only (left center), composite image with Phalloidin (right center), and composite image without Hoechst (right).



**Western blot of Jurkat lysates labeled with rabbit anti-PKC- $\theta$  [pT538] (Cat. No. 700043).**

Rabbit anti-PKC- $\theta$  [pT538] (3  $\mu$ g/mL) was used to label PKC- $\theta$  [pT538] in Jurkat lysates stimulated with 100ng/mL PMA for 1 h (lane 1). Pre-incubation with the phosphopeptide used for immunization resulted in loss of signal (lane 2) whereas pre-incubation with the non-phosphopeptide did not (lane 3).

**For research use only. CAUTION: Not intended for human or animal therapeutic or diagnostic use.**

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.

Rev. 0.0

FORM-00089